Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Assets (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Current Assets data on record, last reported at $66.5 million in Q3 2025.

  • For Q3 2025, Current Assets rose 38.97% year-over-year to $66.5 million; the TTM value through Sep 2025 reached $66.5 million, up 38.97%, while the annual FY2024 figure was $60.1 million, 14.09% down from the prior year.
  • Current Assets reached $66.5 million in Q3 2025 per PLX's latest filing, up from $65.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $95.9 million in Q2 2021 and bottomed at $44.9 million in Q4 2022.
  • Average Current Assets over 5 years is $65.3 million, with a median of $65.5 million recorded in 2025.
  • Peak YoY movement for Current Assets: soared 76.95% in 2021, then tumbled 48.19% in 2022.
  • A 5-year view of Current Assets shows it stood at $61.7 million in 2021, then dropped by 27.22% to $44.9 million in 2022, then soared by 55.82% to $69.9 million in 2023, then fell by 14.09% to $60.1 million in 2024, then rose by 10.69% to $66.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $66.5 million in Q3 2025, $65.5 million in Q2 2025, and $60.5 million in Q1 2025.